Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07024680 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC

Study acronym: PRCC
StatusCompleted
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial completed Final enrollment: 48 participants (planned 150) · Primary completion date changed from estimate of Jul 14, 2026 to May 6, 2026 · Eligibility criteria expanded, about 8 words · 2 more Show 5 more changesShow less
    • Final enrollment: 48 participants (planned 150)
    • Primary completion date changed from estimate of Jul 14, 2026 to May 6, 2026
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints: details revised at 1 of 1 entry
    • Site details revised
  2. Primary and study completion dates: Oct 30, 2025 to Jul 14, 2026v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
727 trials monitored
See 61 trials at risk
Kidney Cancer
772 trials monitored
See 53 trials at risk
This is a multi-center, observational, retrospective study designed to characterize the effectiveness and safety of sunitinib or sorafenib monotherapy in the treatment of Chinese adult patients with unresectable and locally advanced or metastatic PRCC, who have not received any prior systemic anticancer therapy in the metastatic setting. Electronic medical record (EMR) data of patients with 1L sunitinib or sorafenib monotherapy will be screened from Grade-A Tertiary hospitals in China. The study period is from 1st September 2007 to 31st December 2024.
Trial Details
NCT Number NCT07024680
Lead Sponsor AstraZeneca
Conditions Papillary Renal Cell Carcinoma
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov